Glypican-3 (GPC3) is a promising therapeutic target for HCC because high expression of GPC3 is associated with advanced HCC, high tumor grade, vascular invasion, short survival, and poor prognosis, and immunohistochemical GPC3 reactivity reflects tumor staging 94. Here, GPC3 is linked to hepatocellular carcinoma.